

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Lead Product(s) : UNII-38R1Q0L1ZE
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Telix Pharmaceuticals | National Cancer Institute | National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes
Details : Fluciclovine F18 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 04, 2018
Lead Product(s) : UNII-38R1Q0L1ZE
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Telix Pharmaceuticals | National Cancer Institute | National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : UNII-38R1Q0L1ZE
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Bital Savir-Baruch
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fluciclovine F18 is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Uterine Cervical Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 21, 2017
Lead Product(s) : UNII-38R1Q0L1ZE
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Bital Savir-Baruch
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : UNII-38R1Q0L1ZE
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GE-148 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 06, 2010
Lead Product(s) : UNII-38R1Q0L1ZE
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
